The head of Turing pharmaceuticals has backed down from plans to dramatically raise the price of a 62-year-old drug used by AIDS patients. Peter Maybarduk works on public access to drugs issues with the "Public Citizen" lobby group in Washington, D.C.
Recent stories from Morning Report
Get the RNZ app
for easy access to all your favourite programmes
